| Nov 7 |
CEL-SCI, FDA agree on Phase 3 trial design for cancer drug
|
| Nov 7 |
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
|
| Oct 22 |
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
|
| Oct 1 |
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
|
| Sep 16 |
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
|
| Sep 10 |
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
|
| Aug 28 |
CVM: Start Your Engines – FDA Green Lights Confirmatory Registration Study
|
| Aug 15 |
Cel-Sci GAAP EPS of -$0.42 misses by $0.31
|
| Aug 15 |
CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
|
| Aug 15 |
Cel-Sci: Fiscal Q3 Earnings Snapshot
|
